Dr. Eric J. Lorraine, DO
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- New York College of Osteo Medicine of New York Institute of Technology (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 202
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: New York College of Osteo Medicine of New York Institute of Technology
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
NY license 268787-1
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- United Health Services Hospitals, Inc Binghamton, NY
- Our Lady of Lourdes Memorial Hospital, Inc Binghamton, NY
- Chenango Memorial Hospital Norwich, NY
Medical groups
- Endwell Family Physicians LLP (26 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 202
- Services billed
- 1,877
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 250 | 143 |
| Insertion of needle into vein for collection of blood sample | 158 | 104 |
| Blood test, comprehensive group of blood chemicals | 142 | 101 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 131 | 96 |
| Blood test, lipids (cholesterol and triglycerides) | 106 | 81 |
| Automated urinalysis test | 57 | 48 |
| Established patient office or other outpatient visit, 20-29 minutes | 43 | 42 |
| Hemoglobin a1c level | 35 | 25 |
| Blood test, thyroid stimulating hormone (tsh) | 34 | 27 |
| Thyroxine (thyroid chemical), free | 29 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 23 payments worth $471 in total to this clinician.
| AbbVie Inc. | $150 |
|---|---|
| Novo Nordisk Inc | $77.68 |
| Lilly USA, LLC | $49.25 |
| Edwards Lifesciences Corporation | $46.21 |
| Verona Pharma, Inc. | $24.24 |
| GlaxoSmithKline, LLC. | $20.39 |
| Pfizer Inc. | $18.73 |
| Phathom Pharmaceuticals, Inc. | $17.41 |
| Food and Beverage | $471 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $317,386 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are…
Amgen Inc. - NB (Contrave) Cardiovascular Outcomes Trial
Currax Pharmaceuticals LLC - A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity
AstraZeneca Pharmaceuticals LP - Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents
Sanofi Pasteur Inc. · Active, not recruiting · NCT06838000 - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421 - A phase 2B, randomized, observer-blinded trial to describe the safety,
GlaxoSmithKline, LLC. - A phase 3B, open-label, multi-country, multi-centre, long-term follow-
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.